China Resources Pharmaceutical Group (OTCPK:CRPGF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
China Resources Pharmaceutical Group EBITDA Margin % Related Terms
China Resources Pharmaceutical Group EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Pharmaceutical Group EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where China Resources Pharmaceutical Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Pharmaceutical Group (CRPGF) has a EBITDA Margin % of 6.24% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Resources Pharmaceutical Group and its competitors. This is near median its historical median of 6.38. Over the past decade, China Resources Pharmaceutical Group's EBITDA Margin % has ranged from 5.90 to 7.24. According to the industry distribution chart, China Resources Pharmaceutical Group ranks #611 out of 953 companies in the Drug Manufacturers industry, placing it in the top 64.1%.
Is China Resources Pharmaceutical Group's EBITDA Margin % too high?
China Resources Pharmaceutical Group's current EBITDA Margin % of 6.24% is near median its 10-year median of 6.38. Over the past 10 years, this metric has ranged from a low of 5.90 to a high of 7.24. The Drug Manufacturers industry median EBITDA Margin % is 12.54. China Resources Pharmaceutical Group's value of 6.24% is 50.2% below this industry median. Based on the distribution chart, China Resources Pharmaceutical Group ranks #611 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China Resources Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Resources Pharmaceutical Group's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Pharmaceutical Group ranks #611 out of 953 companies for EBITDA Margin %. This places China Resources Pharmaceutical Group in the lower half of its industry. The industry median EBITDA Margin % is 12.54. China Resources Pharmaceutical Group's value of 6.24% is 50.2% below this benchmark. Historically, China Resources Pharmaceutical Group's own EBITDA Margin % has ranged from 5.90 to 7.24 over the past decade. While the company's 10-year median is 6.38 vs. the industry median of 12.54, China Resources Pharmaceutical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Pharmaceutical Group's current EBITDA Margin % of 6.24% is 50.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on China Resources Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Pharmaceutical Group's current EBITDA Margin % is 6.24%, which is near median its own 10-year median of 6.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Pharmaceutical Group stock overvalued right now?
China Resources Pharmaceutical Group (CRPGF) has a current EBITDA Margin % of 6.24%. The stock's GF Value™ is $0.77, compared to a current price of $0.56 — trading 27.3% below its estimated fair value. The current EBITDA Margin % is 6.24%, which is near median its 10-year median of 6.38 and 50.2% below the Drug Manufacturers industry median of 12.54. China Resources Pharmaceutical Group's overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For China Resources Pharmaceutical Group (CRPGF), the current EBITDA Margin % is 6.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Pharmaceutical Group (CRPGF) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Pharmaceutical Group stock appears to be undervalued.
The current stock price of $0.56 is trading 27.3% below its estimated GF Value™ of $0.77.
Key valuation signals for CRPGF:
EBITDA Margin %: 6.24% (near median its 10-year median of 6.38)
GF Value™: $0.77 vs. price of $0.56 (27.3% below fair value)
Industry Position: 50.2% below the Drug Manufacturers median (#611 of 953)
No single metric tells the full story. See the CRPGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Pharmaceutical Group Business Description
China Resources Pharmaceutical Group Ltd is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products. Specifically, the Group has four reportable segments as follows: Pharmaceutical manufacturing business, Pharmaceutical distribution business, Pharmaceutical retail business , and Other business operations. The company generates majority of its revenue from the Pharmaceutical distribution business.
92GF Score
Get the complete analysis for CRPGF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRPGF has been successfully added to your 
